Erratum to “Addition of Metanx in Pregabalin Partial Responders for Painful Diabetic Neuropathy”

DOI: 10.4236/jdm.2014.43035   PDF   HTML   XML   2,679 Downloads   3,185 Views  


Objective: To study the effect of addition of Metanx on burning parasthesias in patients with symptomatic diabetic neuropathy who had obtained only partial symptom resolution with pregabalin. Research design and methods: This was an open-label pilot study. There were 16 patients (7 males, 9 females) in the study group and 8 patients (3 males, 5 females) in the control group. A patient numeric rating scale (0 - 10) of neuropathy associated pain was obtained at baseline and at 20 weeks. The control group continued on a fixed dosage of pregabalin without additional medication, while the study group was supplemented with Metanx (a proprietary blend of bioactive B-vitamins), in addition to being continued on a fixed dosage of pregabalin. Results: After 20 weeks, significantly more patients in the study group experienced pain relief compared to the control group (87.5% vs. 12.5%, respectively, p =0.005). The average pain score reduction after 20 weeks in the study group was 3 compared to0.25 inthe control group (p < 0.001). Conclusion: Our study suggested that addition of Metanx may be used for the relief of pain in patients that have obtained only partial resolution of symptomatology from pregabalin.

Share and Cite:

Jacobs, A. and Cheng, D. (2014) Erratum to “Addition of Metanx in Pregabalin Partial Responders for Painful Diabetic Neuropathy”. Journal of Diabetes Mellitus, 4, 249-249. doi: 10.4236/jdm.2014.43035.

Conflicts of Interest

The authors declare no conflicts of interest.

comments powered by Disqus

Copyright © 2020 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.